JP2003534281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003534281A5 JP2003534281A5 JP2001585780A JP2001585780A JP2003534281A5 JP 2003534281 A5 JP2003534281 A5 JP 2003534281A5 JP 2001585780 A JP2001585780 A JP 2001585780A JP 2001585780 A JP2001585780 A JP 2001585780A JP 2003534281 A5 JP2003534281 A5 JP 2003534281A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cells
- apoptotic
- patient
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001640 apoptogenic effect Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 9
- 210000000601 blood cell Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2,309,518 | 2000-05-25 | ||
| CA 2309518 CA2309518A1 (en) | 2000-05-25 | 2000-05-25 | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
| PCT/CA2001/000758 WO2001089536A2 (en) | 2000-05-25 | 2001-05-25 | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003534281A JP2003534281A (ja) | 2003-11-18 |
| JP2003534281A5 true JP2003534281A5 (enExample) | 2008-07-10 |
Family
ID=4166254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001585780A Withdrawn JP2003534281A (ja) | 2000-05-25 | 2001-05-25 | Ｔ細胞媒介性及び炎症性疾患の治療における使用のためのアポトーシス体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20020051771A1 (enExample) |
| EP (2) | EP1289534B1 (enExample) |
| JP (1) | JP2003534281A (enExample) |
| AT (1) | ATE311191T1 (enExample) |
| AU (1) | AU2001261986A1 (enExample) |
| CA (1) | CA2309518A1 (enExample) |
| DE (1) | DE60115432T2 (enExample) |
| DK (1) | DK1289534T3 (enExample) |
| ES (1) | ES2254424T3 (enExample) |
| TW (1) | TWI249404B (enExample) |
| WO (1) | WO2001089536A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309424A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
| CA2327631A1 (en) * | 2000-12-05 | 2002-06-05 | Vasogen Ireland Limited | Inflammatory cytokine secretion inhibition |
| CA2457015C (en) * | 2001-08-13 | 2012-03-13 | Richard L. Edelson | Method for inducing selectively suppressed immune response |
| US7727523B2 (en) * | 2001-08-13 | 2010-06-01 | Yale University | Method for suppressing immune system response to transplanted tissue or cells |
| JP2005517637A (ja) * | 2001-11-29 | 2005-06-16 | セラコス・インコーポレイテッド | 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法 |
| US8524495B2 (en) | 2007-05-16 | 2013-09-03 | Yale University | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| CA2893962C (en) * | 2012-12-06 | 2021-04-06 | Enlivex Therapeutics Ltd | Therapeutic apoptotic cell preparations, method for producing same and uses thereof |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11512289B2 (en) * | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
| JP6884155B2 (ja) * | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
| WO2023209709A1 (en) * | 2022-04-27 | 2023-11-02 | Enlivex Therapeutics Rdo Ltd | Apoptotic cell - chemotherapy combination therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
| CA2309417A1 (en) * | 2000-05-25 | 2001-11-25 | Anthony E. Bolton | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| CA2309424A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
| JP2005517637A (ja) * | 2001-11-29 | 2005-06-16 | セラコス・インコーポレイテッド | 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法 |
-
2000
- 2000-05-25 CA CA 2309518 patent/CA2309518A1/en not_active Abandoned
-
2001
- 2001-05-25 WO PCT/CA2001/000758 patent/WO2001089536A2/en not_active Ceased
- 2001-05-25 DE DE2001615432 patent/DE60115432T2/de not_active Expired - Fee Related
- 2001-05-25 ES ES01935896T patent/ES2254424T3/es not_active Expired - Lifetime
- 2001-05-25 JP JP2001585780A patent/JP2003534281A/ja not_active Withdrawn
- 2001-05-25 DK DK01935896T patent/DK1289534T3/da active
- 2001-05-25 AT AT01935896T patent/ATE311191T1/de not_active IP Right Cessation
- 2001-05-25 EP EP01935896A patent/EP1289534B1/en not_active Expired - Lifetime
- 2001-05-25 AU AU2001261986A patent/AU2001261986A1/en not_active Abandoned
- 2001-05-25 US US09/866,488 patent/US20020051771A1/en not_active Abandoned
- 2001-05-25 EP EP20050025962 patent/EP1669081A1/en not_active Withdrawn
- 2001-06-01 TW TW90113342A patent/TWI249404B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0858343B1 (en) | Continuous low-dose cytokine infusion therapy | |
| CA2263911A1 (en) | Treatment of autoimmune diseases | |
| WO2001060381B1 (en) | Nucleoside analogs with carboxamidine-modified bicyclic base | |
| Lindberg et al. | Trigger factors and HL-A antigens in chronic active hepatitis | |
| CA2229282A1 (en) | Use of hyaluronic acid as an immunosuppressant | |
| CA2518219A1 (en) | Igf-binding protein-derived peptide or small molecule | |
| WO2020041533A1 (en) | Compositions and methods for treating diseases associated with uncontrolled inflammatory responses | |
| JP2002534479A5 (enExample) | ||
| Schwartz et al. | Extracorporeal photochemotherapy in progressive systemic sclerosis: a follow‐up study | |
| JP2003534282A5 (enExample) | ||
| Graham‐Brown et al. | Scleroderma‐like changes due to chronic graft‐versus‐host disease | |
| Chang et al. | ENTECAVIR MAINTAINED VIROLOGIC SUPPRESSION THROUGH 3 YEARS OF TREATMENT IN ANTIVIRALNAïVE HBEAG (+) PATIENTS (ETV 022/901): 109 | |
| JP2005508829A5 (enExample) | ||
| EP1352955A3 (en) | HLA matching donor-originating activated lymphocytes to be used in prevention/treatment of tumors, infectious diseases and autoimmune diseases, treatment method achieved by using the lymphocytes, formula having the lymphocytes as a main constitutuent thereof, method for manufacturing the formula and preparation kit to be used to prepare the formula | |
| Schorlemmer et al. | Immunomodulatory activity of recombinant IL-1 receptor (IL-1-R) on models of experimental rheumatoid arthritis | |
| Leonidas et al. | Haiti and the acquired immunodeficiency syndrome | |
| Nair et al. | Effect of cocaine on chemokine and CCR-5 gene expression by mononuclear cells from normal donors and HIV-1 infected patients | |
| JP2000178203A5 (enExample) | ||
| CN201294024Y (zh) | 老年病人专用保健呼叫器 | |
| Gomes | A Case of Dermatomyositis: Diagnostic Challenge in Low Resource Settings | |
| Highleyman | IL-2 flushes out HIV | |
| Randall | Gene Scene: A Master Control Switch for Myogenesis Muscles Its Way Into the Clinic | |
| Mobini | Severe muscle weakness during treatment with pegylated interferon alfa for chronic hepatitis C virus infection; A rare complication | |
| GB9617611D0 (en) | Treatment of autoimmune disease | |
| CN103920136A (zh) | 胸腺五肽peg化衍生物为活性成分的肠释药制剂及用途 |